Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Molibresib (besylate) | 1895049-20-3 | 97.0% | 50 MG
Supplier: Medchemexpress LLC HY13032B50MG
Molibresib besylate is an orally active pan-BET inhibitor that targets BRD2, BRD3, BRD4, and BRDT. It disrupts the interaction between BET proteins and chromatin, inhibiting MYC expression and target gene transcription. This compound exhibits broad antiproliferative activity, inhibiting cancer cell growth and inducing growth arrest. It is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer, and various advanced refractory solid tumors.
- Orally active pan-BET inhibitor.
- Targets BRD2, BRD3, BRD4, and BRDT.
- Inhibits MYC expression and target gene transcription.
- Exhibits broad antiproliferative activity.
- Shows synergistic effect with MEK inhibitors.
- Applicable for research in acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, and small-cell lung cancer.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?